NASDAQ:HARP - Harpoon Therapeutics Stock Price, Forecast & News

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Harpoon Therapeutics Inc (NASDAQ:HARP) issued its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by $0.09. The company earned $1.42 million during the quarter, compared to the consensus estimate of $1.09 million. Harpoon Therapeutics had a negative return on equity of 86.88% and a negative net margin of 1,107.97%. View Harpoon Therapeutics' Earnings History.

Harpoon Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Harpoon Therapeutics.

6 Wall Street analysts have issued 1-year price targets for Harpoon Therapeutics' shares. Their forecasts range from $23.00 to $26.00. On average, they anticipate Harpoon Therapeutics' share price to reach $24.40 in the next twelve months. This suggests a possible upside of 67.9% from the stock's current price. View Analyst Price Targets for Harpoon Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Harpoon Therapeutics.

Media stories about HARP stock have trended positive this week, according to InfoTrie. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Harpoon Therapeutics earned a daily sentiment score of 3.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Harpoon Therapeutics.

Harpoon Therapeutics saw a drop in short interest in the month of December. As of December 13th, there was short interest totalling 244,500 shares, a drop of 9.1% from the November 28th total of 269,000 shares. Based on an average daily trading volume, of 71,200 shares, the days-to-cover ratio is currently 3.4 days. Approximately 1.8% of the shares of the company are short sold. View Harpoon Therapeutics' Current Options Chain.

Some companies that are related to Harpoon Therapeutics include Orchard Therapeutics (ORTX), Coherus Biosciences (CHRS), Alector (ALEC), Cortexyme (CRTX), DBV TECHNOLOGIE/S (DBVT), Aerie Pharmaceuticals (AERI), NanoString Technologies (NSTG), Sangamo Therapeutics (SGMO), Krystal Biotech (KRYS), BAVARIAN NORDIC/S (BVNRY), Atara Biotherapeutics (ATRA), AVITA MED LTD/S (RCEL), Mesoblast (MESO), GENFIT S A/ADR (GNFT) and Cellectis (CLLS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Alector (ALEC), Editas Medicine (EDIT), NVIDIA (NVDA), Universal Display (OLED), PhaseBio Pharmaceuticals (PHAS), Advanced Micro Devices (AMD), Activision Blizzard (ATVI), Cisco Systems (CSCO), Docusign (DOCU) and Precision BioSciences (DTIL).

(HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HARP stock can currently be purchased for approximately $14.53.

Harpoon Therapeutics has a market capitalization of $357.99 million and generates $4.75 million in revenue each year. The company earns $-27,370,000.00 in net income (profit) each year or ($25.65) on an earnings per share basis. Harpoon Therapeutics employs 45 workers across the globe.View Additional Information About Harpoon Therapeutics.

The official website for Harpoon Therapeutics is http://www.harpoontx.com/.

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]